The effect of catheter displacement on acute and late toxicity in fractionated HDR monotherapy of prostate cancer

被引：0
|
作者：
Aluwini, S. [1 ]
Bhawanie, A. [1 ]
Baartman, L. [1 ]
Alemayehu, W. Ghidey [2 ]
Busser, W. [1 ]
Boormans, J. [3 ]
Kolkman-Deurloo, I. K. [1 ]
机构：
[1] Erasmus MC, Dept Radiat Oncol, Inst Canc, Rotterdam, Netherlands
[2] Erasmus MC, Clin Trials Ctr, Inst Canc, Rotterdam, Netherlands
[3] Erasmus MC, Inst Canc, Dept Urol, Rotterdam, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2015年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OC-0036
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [41] HDR monotherapy (2 fractions/13,5 Gy) in LR and favorable IR prostate cancer: analysis of toxicity
    Rodriguez Villalba, S.
    Monasor Denia, P.
    Richart Sancho, J.
    Acosta Rojas, A.
    Perez-Calatayud, M. J.
    Perez-Calatayud, J.
    Santos Ortega, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S200 - S200
  • [42] Measurement of cranio-caudal catheter displacement between fractions in CT-based HDR brachytherapy of prostate cancer
    Kim, Y
    Hsu, I
    Pouliot, J
    MEDICAL PHYSICS, 2005, 32 (06) : 1957 - 1957
  • [43] Assessment of acute toxicity with HDR focal boost and whole gland SBRT in localised prostate cancer
    Padayachee, J.
    Liu, Z.
    Berlin, A.
    Helou, J.
    Winter, J.
    Kong, V.
    Glicksman, R.
    Raman, S.
    Weersink, R.
    Chung, P.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S508 - S509
  • [44] Factors predicting acute and late gastrointestinal and genitourinary toxicity in prostate cancer
    Arcelli, A.
    Deodato, F.
    Buwenge, M.
    Ntreta, M.
    Siepe, G.
    Ndoci, E.
    Zamagni, A.
    Bisello, S.
    Alexopoulou, E.
    Macchia, G.
    Cilla, S.
    Morganti, A. G.
    Frezza, G. P.
    Cammelli, S.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S22 - S22
  • [45] Acute- and late toxicity after percutaneous radiotherapy of prostate cancer
    Brinkmann, R.
    Niewald, M.
    Fleckenstein, V.
    Wullich, B.
    Ruebe, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 117 - 117
  • [46] Quality assurance in HDR brachytherapy for prostate cancer: how can prostate displacement be minimized?
    Guix, B
    Bartrina, JM
    Serrate, R
    Tello, JI
    Vendrell, JR
    Henriquez, I
    RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S109 - S109
  • [47] 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer
    Kurek, R
    Shazikis, G
    Martin, T
    Baltas, D
    Anagnostopoulos, G
    Röddiger, SJ
    Sapoutzis, N
    Buhleier, T
    Dannenberg, T
    Tunn, UW
    Zamboglou, N
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 7 - 7
  • [48] HDR monotherapy for low and intermediate risk prostate cancer in one or two fractions
    Biryukov, V.
    Obukhov, A. A.
    Borysheva, N. B.
    Lepilina, O. G.
    Sanin, D. B.
    Mikhailovsky, N. V.
    Karyakin, O. B.
    Ivanov, S. A.
    Kaprin, A. D.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S199 - S200
  • [49] What is the proper dose in single fraction HDR brachytherapy as monotherapy for prostate cancer?
    Ruiz Arrebola, S.
    Tornero-Lopez, A. M.
    De la Vega, J. M.
    Prada, P. J.
    Guirado, D.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S972 - S973
  • [50] HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis
    Viani, Gustavo Arruda
    Arruda, Caio Viani
    Assis Pellizzon, Antonio Cassio
    De Fendi, Ligia Issa
    BRACHYTHERAPY, 2021, 20 (02) : 307 - 314
12345